DPP4 and metabolic dysfunction-associated steatotic liver disease: Likewise, no data about the effects of dipeptidyl peptidase 4 (DPP4) inhibitors on liver histology of NAFLD patients is available, despite vildagliptin being shown to reduce MRI-measured liver fat content [227].